- Home
- VSEC vs PTGX Comparison
VSEC vs PTGX Comparison
Compare VSEC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSEC | PTGX |
|---|---|---|
| Founded | 1959 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.2B |
| IPO Year | 1995 | 2016 |
Fundamental Metrics
Financial Performance| Metric | VSEC | PTGX |
|---|---|---|
| Price | $222.71 | $86.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $221.71 | $99.20 |
| AVG Volume (30 Days) | ★ 705.6K | 580.2K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | N/A | ★ 404.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $760,113,000.00 | N/A |
| Revenue This Year | $3.78 | N/A |
| Revenue Next Year | $21.59 | $501.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.88 | N/A |
| 52 Week Low | $98.27 | $33.70 |
| 52 Week High | $229.02 | $96.54 |
Technical Indicators
Market Signals| Indicator | VSEC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 58.66 |
| Support Level | $158.16 | $83.82 |
| Resistance Level | $225.00 | $86.81 |
| Average True Range (ATR) | 10.15 | 3.59 |
| MACD | 1.75 | 0.34 |
| Stochastic Oscillator | 84.50 | 96.90 |
Price Performance
Historical ComparisonAbout VSEC VSE Corporation
VSE Corp is a diversified aftermarket products and services company providing repair services, parts distribution, logistics, supply chain management, and consulting services for land, sea, and air transportation assets to commercial and government markets. Its operations include supply chain management solutions, parts supply and distribution, and maintenance, repair, and overhaul (MRO) services for vehicle fleet, aviation, maritime and other customers. Its reportable segments are; Aviation and Fleet. The majority of the revenue for the company is generated from the Aviation segment which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.